Navigation Links
Optimer Pharmaceuticals Reports Third Quarter 2009 Financial Results
Date:11/3/2009

SAN DIEGO, Nov. 3 /PRNewswire-FirstCall/ -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today reported financial results for the third quarter ended September 30, 2009. Optimer reported a net loss for the third quarter of 2009 of $9.4 million, or $0.28 per share, which was in line with the Company's expectations. This compares to a net loss for the third quarter of 2008 of $9.2 million, or $0.31 per share. Research and development expenses in the third quarter of 2009 were $7.2 million, compared to $7.9 million in the third quarter of 2008. The decrease was primarily due to the completion of the Pruvel(TM)(prulifloxacin) Phase 3 trials. The decrease was partially offset by an increase in expenses to prepare regulatory filings related to fidaxomicin and Pruvel.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

As of September 30, 2009, Optimer held cash, cash equivalents and short-term investments of $42.5 million.

"It's been another strong quarter for Optimer, marked by significant interaction with the medical community on the Phase 3 data profiling the characteristics and attributes of fidaxomicin and Pruvel," said Michael N. Chang, Ph.D., Optimer's President and Chief Executive Officer. "Additional data from the North American Phase 3 fidaxomicin trial were recently presented at the ICAAC and IDSA medical conferences further demonstrating why we believe fidaxomicin has the potential to be the optimal treatment for CDI."

Corporate Updates

  • Following discussions with the FDA, Optimer has elevated global cure to a secondary endpoint from an exploratory endpoint in the second Phase 3 fidaxomicin trial. Given the
    '/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Optimer Pharmaceuticals to Present at September 2009 Investor Conferences
2. Optimer Pharmaceuticals Announces Presentations of Additional Phase 3 Fidaxomicin and Prulifloxacin Data at Upcoming ICAAC Annual Meeting
3. Optimer Pharmaceuticals Reports Second Quarter 2009 Financial Results
4. Optimer Pharmaceuticals to Present at the Canaccord Adams 29th Annual Global Growth Conference
5. Optimer Pharmaceuticals to Present at June 2009 Investor Conferences
6. Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI
7. Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results
8. ISTA Pharmaceuticals Reports Third Quarter 2009 Financial Results
9. Poniard Pharmaceuticals Reports Third Quarter 2009 Financial Results and Provides a Corporate Update
10. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
11. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   GenoSpace , a leading provider ... analysis of genomic and other biomedical data, today ... the company as Vice President of Sales and ... "GenoSpace partners with its customers ... and explore complex sets of genomic, phenotypic and ...
(Date:7/30/2015)... CA (PRWEB) , ... July 30, 2015 , ... ... successful completion of a field clinical study of its canine osteoarthritis stem cell ... with Aratana Therapeutics (Kansas City, KS) and will be marketed in the US ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
Breaking Biology Technology:GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2
... ... , ... (PRWEB) October 21, 2009 -- iLife Americas, LLC, a leading developer and marketer of ... its line of iLife wellness and therapeutic products. Officially opened on September 1, 2009, ...
... -- China Medical Technologies,Inc. (the "Company") (Nasdaq: CMED ), ... advanced in-vitro diagnostic,products, today announced that it will attend the ... October 31, 2009 in Chengdu,China. , , ... China International Medical Equipment Fair, Date: ...
... created a new material that would allow a fingernail-size ... DVDs or 250 million pages of text, far exceeding ... Led by Dr. Jagdish "Jay" Narayan, John C.C. Fan ... director of the National Science Foundation Center for Advanced ...
Cached Biology Technology:iLife Americas, LLC Enters U.S. Wellness and Therapeutic Markets 2China Medical Technologies to Exhibit its Products at China International Medical Equipment Fair in Chengdu, China 2New material could boost data storage, save energy 2
(Date:7/31/2015)... , July 31, 2015 The 10 th ... be held by BGI from October 22-25, 2015, in ... The conference is celebrating its 10 th anniversary this ... of the world,s most influential annual meetings in the ,omics, ... enjoyable scientific gatherings. ICG-10 focuses on recent ...
(Date:7/23/2015)... -- Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2015.  ... a decrease of 33% compared to $6.8 million in the ... of 2015 was $0.3 million, or $0.01 per diluted share, ... in the same period a year ago.  ...
(Date:7/21/2015)... NEW YORK , July 21, 2015 /PRNewswire/ ... critical systems, as seen in the recent U.S. ... enterprises a solution to the infosec conundrum, but ... data is stored. To address this dilemma, Biometrics-as-a-Service ... of its Biometric Tokenization SDK for third party ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
... CITY After years of working toward this goal, scientists ... isolate cancer stem cells in tumors so they can target ... A research team at the University of Oklahoma led ... a particular protein only appears in stem cells. Until now, ...
... KNOXVILLE -- Two research groups from the University of ... National Science Foundation to create new graduate research and ... The grants, called Integrative Graduate Education and Research Traineeships, ... graduate students to UT Knoxville for two unique programs ...
... University of Nottingham are to investigate the effect of nutrients ... of keeping up our strength as we get old. ... and Health in Derby, want to know what sort of ... to slow down the natural loss of skeletal muscle with ...
Cached Biology News:UT Knoxville wins 2 $3M National Science Foundation research and education grants 2A stronger future for the elderly 2
Plasmid expressing the LacZ reporter gene....
... flasks have triple baffles located at the ... maximal oxygen transfer to culture medium. These ... wide range of optional caps are available ... caps for ease of sorting and identification ...
...
... mouth PYREX Fernbach-style culture flask is designed for ... volume ratio. It can also be used in ... edges to achieve maximal oxygen transfer to culture ... and accepts cotton plugs or No. 13 rubber ...
Biology Products: